BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

414 related articles for article (PubMed ID: 16482210)

  • 61. Molecular monitoring of BCR-ABL as a guide to clinical management in chronic myeloid leukaemia.
    Hughes T; Branford S
    Blood Rev; 2006 Jan; 20(1):29-41. PubMed ID: 16426942
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Monitoring molecular response by BCR-ABL, JH and WT-1 in Ph+ all treated with imatinib containing regimen: preliminary report of two cases.
    Miglino M; Varaldo R; Colombo N; Grasso R; Clavio M; Garuti A; Aquino S; Albarello A; Sessarego M; Gobbi M
    J Exp Clin Cancer Res; 2006 Sep; 25(3):321-4. PubMed ID: 17167971
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Extended follow-up of patients treated with imatinib mesylate (gleevec) for chronic myelogenous leukemia relapse after allogeneic transplantation: durable cytogenetic remission and conversion to complete donor chimerism without graft-versus-host disease.
    DeAngelo DJ; Hochberg EP; Alyea EP; Longtine J; Lee S; Galinsky I; Parekkedon B; Ritz J; Antin JH; Stone RM; Soiffer RJ
    Clin Cancer Res; 2004 Aug; 10(15):5065-71. PubMed ID: 15297408
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Molecular monitoring of response to imatinib (Glivec) in chronic myeloid leukemia patients: experience at a tertiary care hospital in Saudi Arabia.
    Khalil SH; Abu-Amero KK; Al Mohareb F; Chaudhri NA
    Genet Test Mol Biomarkers; 2010 Feb; 14(1):67-74. PubMed ID: 19943786
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Real-time quantification for BCR-ABL transcripts in chronic myeloid leukaemia patients in UKMMC, Malaysia.
    Wong FL; Hamidah NH; Hawa AA; Nurul AN; Leong CF; Saw F; Ainoon O
    Malays J Pathol; 2011 Dec; 33(2):107-12. PubMed ID: 22299211
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Patients with chronic myeloid leukemia who maintain a complete molecular response after stopping imatinib treatment have evidence of persistent leukemia by DNA PCR.
    Ross DM; Branford S; Seymour JF; Schwarer AP; Arthur C; Bartley PA; Slader C; Field C; Dang P; Filshie RJ; Mills AK; Grigg AP; Melo JV; Hughes TP
    Leukemia; 2010 Oct; 24(10):1719-24. PubMed ID: 20811403
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Detection of bcr/abl transcripts by RT-PCR and their colorimetric evaluation in chronic myeloid leukemia patients receiving allogeneic bone marrow transplantation.
    Santini V; Zoccolante A; Bosi A; Guidi S; Saccardi R; Vannucchi AM; Martinazzo G; Bernabei PA; Ferrini PR
    Haematologica; 1996; 81(3):201-7. PubMed ID: 8767524
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Monitoring twenty-six chronic myeloid leukemia patients by BCR-ABL mRNA level in bone marrow:a single hospital experience.
    Sakamoto Y; Mariya Y; Oshikiri T; Sasaki S; Segawa M; Teshiromori R; Ogura K; Akagi T; Kaimori M; Kubo K
    Acta Med Okayama; 2011 Oct; 65(5):335-42. PubMed ID: 22037271
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Successful peripheral blood stem cell mobilisation with filgrastim in patients with chronic myeloid leukaemia achieving complete cytogenetic response with imatinib, without increasing disease burden as measured by quantitative real-time PCR.
    Hui CH; Goh KY; White D; Branford S; Grigg A; Seymour JF; Kwan YL; Walsh S; Hoyt R; Trickett A; Rudzki B; Ma DD; To LB; Hughes TP
    Leukemia; 2003 May; 17(5):821-8. PubMed ID: 12750692
    [TBL] [Abstract][Full Text] [Related]  

  • 70. [A clinical and laboratory study of chronic myeloid leukemia with atypical BCR-ABL fusion gene subtypes].
    Gui X; Pan J; Qiu H; Cen J; Xue Y; Chen S; Shen H; Yao L; Zhang J; Wu Y; Chen Y
    Zhonghua Xue Ye Xue Za Zhi; 2014 Mar; 35(3):210-4. PubMed ID: 24666486
    [TBL] [Abstract][Full Text] [Related]  

  • 71. [Comparison of simultaneous bone marrow cytogenetic and peripheral blood molecular responses in chronic myeloid leukemia].
    Lai Y; Qin Y; Huang X; Jiang Q
    Zhonghua Xue Ye Xue Za Zhi; 2014 Feb; 35(2):104-8. PubMed ID: 24606648
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Quantitative monitoring of BCR/ABL transcript during STI-571 therapy.
    Wu CJ; Neuberg D; Chillemi A; McLaughlin S; Hochberg EP; Galinsky I; DeAngelo D; Soiffer RJ; Alyea EP; Capdeville R; Stone RM; Ritz J
    Leuk Lymphoma; 2002 Dec; 43(12):2281-9. PubMed ID: 12613514
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Prediction of relapse by day 100 BCR-ABL quantification after allogeneic stem cell transplantation for chronic myeloid leukemia.
    Asnafi V; Rubio MT; Delabesse E; Villar E; Davi F; Damaj G; Hirsch I; Dhédin N; Vernant JP; Varet B; Buzyn A; Macintyre E
    Leukemia; 2006 May; 20(5):793-9. PubMed ID: 16541140
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Follow-up of childhood chronic myelogenous leukemia with monitoring the BCR-ABL fusion gene expression in peripheral blood.
    Horváth A; Baghiu MD; Pap Z; Bănescu C; Mărginean CO; Pávai Z
    Rom J Morphol Embryol; 2011; 52(3):907-13. PubMed ID: 21892537
    [TBL] [Abstract][Full Text] [Related]  

  • 75. The early molecular response to imatinib predicts cytogenetic and clinical outcome in chronic myeloid leukaemia.
    Wang L; Pearson K; Ferguson JE; Clark RE
    Br J Haematol; 2003 Mar; 120(6):990-9. PubMed ID: 12648069
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Correlations between cytogenetic and molecular monitoring among patients with newly diagnosed chronic myeloid leukemia in chronic phase: post hoc analyses of the Rationale and Insight for Gleevec High-Dose Therapy study.
    Akard LP; Cortes JE; Albitar M; Goldberg SL; Warsi G; Wetzler M; Ericson SG; Radich JP
    Arch Pathol Lab Med; 2014 Sep; 138(9):1186-92. PubMed ID: 24308645
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Imatinib induces a cytogenetic response in blast crisis or interferon failure chronic myeloid leukemia patients with e19a2 BCR-ABL transcripts.
    Lee JJ; Kim HJ; Kim YJ; Lee S; Hwang JY; Kim YL; Kim DW
    Leukemia; 2004 Sep; 18(9):1539-40. PubMed ID: 15284852
    [No Abstract]   [Full Text] [Related]  

  • 78. [Early monitoring of BCR-ABL transcript levels and cytogenetic in assessing the prognosis of chronic myeloid leukemia].
    Huang Q; Zhang XY; Li Y; Wang XM
    Zhonghua Yi Xue Za Zhi; 2013 Oct; 93(38):3049-53. PubMed ID: 24417926
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Constant BCR-ABL transcript level >or=0.1% (IS) in patients with CML responding to imatinib with complete cytogenetic remission may indicate mutation analysis.
    Poláková KM; Polívková V; Rulcová J; Klamová H; Jurcek T; Dvoráková D; Zácková D; Pospísil Z; Mayer J; Moravcová J
    Exp Hematol; 2010 Jan; 38(1):20-6. PubMed ID: 19837125
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Kinetics of BCR-ABL fusion transcript levels in chronic myeloid leukemia patients treated with STI571 measured by quantitative real-time polymerase chain reaction.
    Stentoft J; Pallisgaard N; Kjeldsen E; Holm MS; Nielsen JL; Hokland P
    Eur J Haematol; 2001; 67(5-6):302-8. PubMed ID: 11872078
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.